Follow The Filings

TXG 10x Genomics

10x Genomics earnings company data as of 4:47 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by TXG's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TXG insider trades
  • None no insider bought on the open market
  • $2.4M sold by 1 insider outside a trading plan
  • $9.1M sold by 4 insiders under 10b5-1 plans
  1. Shehnaaz Suliman Director
    Planned sale
    $465K 5,723 shares at $81.19 19% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  2. Serge Saxonov CEO
    Planned sale
    $2M 25,000 shares at $81.22 2.3% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  3. Adam Taich CFO
    Planned sale
    $3M 46,388 shares at $64.57 13% of stake
    Traded Sep 9 Filed Sep 11
    ↗
  4. John R Stuelpnagel Director
    Sale
    $1.2M 20,000 shares at $61.75 5.7% of stake
    Traded Sep 3 Filed Sep 8
    ↗
  5. Serge Saxonov CEO
    Planned sale
    $668K 10,486 shares at $63.69 1% of stake
    Traded Aug 26 Filed Aug 28
    ↗
  6. Shehnaaz Suliman Director
    Planned sale
    $140K 2,207 shares at $63.65 7% of stake
    Traded Aug 24 Filed Aug 26
    ↗
  7. Sarah A. Teichmann Director
    Planned sale
    $432K 7,551 shares at $57.25 21% of stake
    Traded Aug 13–14 Filed Aug 17
    ↗
  8. John R Stuelpnagel Director
    Sale
    $1.2M 20,000 shares at $57.75 5.4% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  9. Serge Saxonov CEO
    Planned sale
    $1M 30,000 shares at $34.44 2.6% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  10. Shehnaaz Suliman Director
    Planned sale
    $187K 5,723 shares at $32.63 15% of stake
    Traded Jun 16 Filed Jun 18
    ↗
  11. Serge Saxonov CEO
    Planned sale
    $265K 10,718 shares at $24.71 0.9% of stake
    Traded May 26 Filed May 27
    ↗
  12. Serge Saxonov CEO
    Planned sale
    $123K 5,000 shares at $24.56 0.4% of stake
    Traded Apr 14 Filed Apr 16
    ↗
  13. Serge Saxonov CEO
    Planned sale
    $289K 15,000 shares at $19.26 1.3% of stake
    Traded Mar 23–24 Filed Mar 25
    ↗
  14. Serge Saxonov CEO
    Planned sale
    $367K 16,152 shares at $22.73 1.3% of stake
    Traded Mar 2 Filed Mar 4
    ↗
  15. Sarah A. Teichmann Director
    Planned sale
    $147K 7,579 shares at $19.41 22% of stake
    Traded Feb 25 Filed Feb 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 sales to cover taxes, 9 stock grants, 3 gifts, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.